- Home
- TIL vs PIM Comparison
TIL vs PIM Comparison
Compare TIL & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TIL | PIM |
|---|---|---|
| Founded | 2018 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.1M | 160.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TIL | PIM |
|---|---|---|
| Price | $11.32 | $3.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $100.67 | N/A |
| AVG Volume (30 Days) | ★ 73.2K | 57.5K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $63.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.70 | $2.90 |
| 52 Week High | $42.79 | $3.28 |
Technical Indicators
Market Signals| Indicator | TIL | PIM |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 37.36 |
| Support Level | $10.76 | $3.26 |
| Resistance Level | $11.51 | $3.36 |
| Average True Range (ATR) | 0.88 | 0.04 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 24.64 | 14.29 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.